Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia
These findings highlight the potential of martinostat as a selective, low-toxicity HDACi that, combined with TKIs, could provide an effective strategy to overcome drug resistance in CML and improve therapeutic outcomes.
Authors
- Christo Christov (ORCID: https://orcid.org/0000-0003-0570-7278)
- Anne Lorant (ORCID: https://orcid.org/0000-0001-5918-923X)
- Vladimir Li
- Byung Woo Han (ORCID: https://orcid.org/0000-0001-7571-3791)
- Marc Diederich (ORCID: https://orcid.org/0000-0003-0115-4725)
- Gilbert Kirsch
- Dag Erlend Olberg (ORCID: https://orcid.org/0000-0001-7630-675X)
- Haeun Yang
- Michaël Schnekenburger (ORCID: https://orcid.org/0000-0003-0550-9538)
- Guy Bormans (ORCID: https://orcid.org/0000-0002-0335-7190)
- Aloran Mazumder
- Sang Won Cheon
- Barbora Orlikova-Boyer
- Claudia Cerella (ORCID: https://orcid.org/0000-0001-9308-8176)
- Jin‐Young Lee (ORCID: https://orcid.org/0000-0002-6941-5509)
- Su Jung Park (ORCID: https://orcid.org/0000-0002-6122-0790)
- Hyoung Jin Kang
Institutions
- Centre National de la Recherche Scientifique (FR)
- Seoul National University (KR)
- Inserm (FR)
- University of Oslo (NO)
- Hôpital Kirchberg (LU)
- Seoul National University Children's Hospital (KR)
- Laboratoire d'Étude des Microstructures et de Mécanique des Matériaux (FR)
- Norsk Medisinsk Syklotronsenter (Norway) (NO)
- Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
- Université de Lorraine (FR)
- KU Leuven (BE)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1186/s13148-025-01921-0
- Citations
- 1
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81